Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejvs.2025.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Three's Company: Aortic Dissection Trials, Consensus, and Equipoise.
Eur J Vasc Endovasc Surg
July 2025
Department of Surgery and Cancer, Imperial College, London, UK; Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London, UK.
Mitral and/or tricuspid regurgitation in patients undergoing TAVR: two's company, three's a crowd?
Eur Heart J Cardiovasc Imaging
June 2025
Hasselt University, Faculty of Medicine and Life Sciences, Agoralaan, Diepenbeek 3590, Belgium.
Three's company: Membrane waltz among organelles.
Biochim Biophys Acta Bioenerg
August 2025
Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Université Paris-Saclay, Gif-sur-Yvette cedex 91198, France; Inserm U1280, Gif-sur-Yvette cedex 91198, France. Electronic address:
The study of membrane contact sites (MCS) has profoundly transformed our understanding of inter-organelle communication. These sites, where the membranes of two organelles are closely apposed, facilitate the transfer of small molecules such as lipids and ions. They are especially crucial for the maintenance of the structure and function of organelles like mitochondria and lipid droplets, which are largely excluded from vesicular trafficking.
View Article and Find Full Text PDFThree's company: Simultaneous trimodal genome engineering using orthologous Cas proteins.
Mol Ther
January 2025
St John's Institute of Dermatology, King's College London, London, UK. Electronic address:
A next-generation GMMA-based vaccine candidate to fight shigellosis.
NPJ Vaccines
September 2023
GSK Global Health Vaccines R&D (GVGH), Siena, Italy.
Shigellosis is a leading cause of diarrheal disease in low-middle-income countries (LMICs). Effective vaccines will help to reduce the disease burden, exacerbated by increasing antibiotic resistance, in the most susceptible population represented by young children. A challenge for a broadly protective vaccine against shigellosis is to cover the most epidemiologically relevant serotypes among >50 Shigella serotypes circulating worldwide.
View Article and Find Full Text PDF